-
Mashup Score: 0
In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with pruritis due to progressive familial intrahepatic cholestasis and Alagille syndrome, which were presented at EASL Congress. Vig, head of research and development for Mirum Pharmaceuticals Inc., noted Livmarli (maralixibat, Mirum Pharmaceuticals) is currently approved by the FDA for the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0
In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with pruritis due to progressive familial intrahepatic cholestasis and Alagille syndrome, which were presented at EASL Congress. Vig, head of research and development for Mirum Pharmaceuticals Inc., noted Livmarli (maralixibat, Mirum Pharmaceuticals) is currently approved by the FDA for the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
VIDEO with @mirumpharma: #Livmarli reduces serum bile acids and #pruritis in #PFIC, #Alagillesyndrome #EASLCongress #EASL23 @EASLnews https://t.co/nh6KeTdLug
-
-
Mashup Score: 0
In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with pruritis due to progressive familial intrahepatic cholestasis and Alagille syndrome, which were presented at EASL Congress. Vig, head of research and development for Mirum Pharmaceuticals Inc., noted Livmarli (maralixibat, Mirum Pharmaceuticals) is currently approved by the FDA for the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
@MadrigalPharma In a Healio video exclusive, Pam Vig, PhD, of @mirumpharma, highlights new data on #Livmarli for the treatment of #patients with #pruritis due to #progressivefamilialintrahepaticcholestasis and #Alagillesyndrome, which were presented at #EASLCongress. https://t.co/8MFuFOLXXv
-
-
Mashup Score: 1
The FDA has approved Bylvay for the treatment of cholestatic pruritus due to Alagille syndrome in patients aged 12 months or older, according to an Ipsen Biopharmaceuticals press release.This approval marks the second rare cholestatic liver disease indication for Bylvay (odevixibat, Ipsen/Albiero Pharmaceuticals), a non-systemic ileal bile acid transport inhibitor originally approved in 2021 for
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: @US_FDA approves #Bylvay for #cholestaticpruritus due to #Alagillesyndrome #FDANews #GITwitter #MedTwitter https://t.co/twN3p10hxr
-
-
Mashup Score: 4Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: General Medicine News, Latest HeadlinesTweet-
Novel approach prevents liver damage in animal models of #Alagillesyndrome @BCMHouston https://t.co/Pd35rndnTr https://t.co/OQLfIoDPTJ
-
-
Mashup Score: 0
Mirum Pharmaceuticals announced the European Commission has approved Livmarli for the treatment of cholestatic pruritis in patients with Alagille syndrome. “Livmarli’s (maralixibat, Mirum) approval signifies the first and only approved treatment for Alagille syndrome (ALGS) in Europe; it is currently also approved in the U.S. and Israel,” Chris Peetz, president and CEO of Mirum
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: @EU_Commission approves #Livmarli for patients with #Alagillesyndrome @mirumpharma #GITwitter #MedTwitter https://t.co/cEiSd0P0rC
-
-
Mashup Score: 1
Mirum Pharmaceuticals announced the European Commission has approved Livmarli for the treatment of cholestatic pruritis in patients with Alagille syndrome. “Livmarli’s (maralixibat, Mirum) approval signifies the first and only approved treatment for Alagille syndrome (ALGS) in Europe; it is currently also approved in the U.S. and Israel,” Chris Peetz, president and CEO of Mirum
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
. @mirumpharma announced the @EU_Commission has approved #Livmarli for the treatment of #cholestaticpruritis in patients with #Alagillesyndrome #GITwitter #MedTwitter https://t.co/cEiSd0P0rC
-
-
Mashup Score: 0
WASHINGTON D.C. — In a Healio video exclusive, Ron Cooper, CEO of Albireo Pharma, highlighted positive top-line safety and efficacy results of Bylvay for the treatment of Alagille syndrome in patients from birth to early adulthood. In the double-blind, placebo-controlled phase 3 ASSERT trial, patients were randomized 2:1 to receive once-daily 120 g/kg Bylvay (odevixibat, Albireo), a
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
In a @GoHealio #GI video exclusive, Ron Cooper, CEO of @AlbireoPharma, highlighted positive top-line safety and efficacy results of #Bylvay for the treatment of #Alagillesyndrome in patients from birth to early adulthood #TLM2022 #LiverMtg22 #LiverTwitter https://t.co/nrRnKZtmw9 https://t.co/MKRhA8bND1
-
-
Mashup Score: 1
-
“Leung et al on behalf of CHiLDReN report neurodevelopmental outcomes in #pediatric #liver disease: 🧠 Lower IQ with #alagillesyndrome not #A1AT nor #PFIC 🧠 A1AT and ALGS with lower exec function 🧠 Worse outcome from #malnutrition and severe disease https://t.co/GJRq72SZF3”
Read the original tweet here
Source: TwitterCategories: Latest Headlines, PediatricsTweet-
Leung et al on behalf of CHiLDReN report neurodevelopmental outcomes in #pediatric #liver disease: 🧠 Lower IQ with #alagillesyndrome not #A1AT nor #PFIC 🧠 A1AT and ALGS with lower exec function 🧠 Worse outcome from #malnutrition and severe disease https://t.co/TCdp1jh5SA https://t.co/f7vCorh8Gf
-
-
Mashup Score: 0Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Latest Headlines, PediatricsTweet-
Leung et al on behalf of CHiLDReN report neurodevelopmental outcomes in #pediatric #liver disease: 🧠 Lower IQ with #alagillesyndrome not #A1AT nor #PFIC 🧠 A1AT and ALGS with lower exec function 🧠 Worse outcome from #malnutrition and severe disease https://t.co/GJRq72SZF3 https://t.co/logesNOKhU
-
@DrLoomba In a Healio video exclusive, Pam Vig, PhD, of @mirumpharma, highlights new data on #Livmarli for the treatment of patients with #pruritis due to #PFIC and #Alagillesyndrome, which were presented at #EASLCongress. https://t.co/8MFuFOLXXv